Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MARVAX

Financiado

Cerrado

Development of novel viral vectored vaccines against Marburgviruses inducing rob...

Development of novel viral vectored vaccines against Marburgviruses inducing robust and cross-reactive protection The frequency, magnitude, and geographical range of Marburg virus disease outbreaks are expanding, with recent cases emerging in Equatorial Guinea and Tanzania. Marburgviruses, listed among the WHO priority pathogens, have demonst... ver más

30/11/2027

BNI

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

BERNHARDNOCHTINSTITUT FUER TROPENMEDIZIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-23

HORIZON-HLTH-2023-DISEASE-03-18: Pandemic preparedness and response:... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

BNI

1.73M€ | Lider

CSIC

1.24M€ | Participante

2.37M€ | Participante

CZ VETERINARIA

2.10M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AGL2014-57430-R MEJORA Y EVALUACION DE VACUNAS BASADAS EN VECTORES VIRICOS Y... 303K€ Cerrado

SAF2008-02036 BIOLOGIA DEL VIRUS VACCINIA Y SU APLICACION COMO VACUNA CONT... 655K€ Cerrado

FLUNIVAC InFLUenza virus UNIVersal VACcine development program 7M€ Cerrado

OSIRIX Revolutionary vaccines to prevent pandemic and seasonal outb... 4M€ Cerrado

FLU-MAL VLP Chimeric Influenza VLP used as vaccine platform for presenta... 194K€ Cerrado

RTI2018-097625-B-I00 ESTUDIO INMUNIDAD INNATA ENTRENADA CONFERIDA POR LAS VACUNAS... 290K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2023-11-23
Fecha Fin: 2027-11-30

Líder del proyecto

BERNHARDNOCHTINSTITUT FUER TROPENMEDIZIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The frequency, magnitude, and geographical range of Marburg virus disease outbreaks are expanding, with recent cases emerging in Equatorial Guinea and Tanzania. Marburgviruses, listed among the WHO priority pathogens, have demonstrated their epidemic potential. However, no licensed vaccines are available, and outbreaks continue to impose high morbidity and mortality burdens. Vaccine candidates in the pipeline are based on the Marburg virus (MARV) glycoprotein (GP) as a single immunogen. MARVAX ambition is to improve the strength and breadth of MARV vaccines by deploying the measles virus (MV) and modified vaccinia virus Ankara (MVA) viral vector vaccine platforms for expression of several MARV antigens: GP, viral protein 40 (VP40), which together with GP allows the formation of virus-like particles, and the nucleoprotein (NP), which contains conserved epitopes that are the main drivers of T cell responses. We will evaluate in depth the innate, adaptive and memory antigen-specific humoral and cellular cross-protective immune responses induced by MV-MARV and MVA-MARV vaccine candidates against MARV, Ravn virus and ebolaviruses, in single dose and in homologous and heterologous prime/boost immunization regimens, through an innovative preclinical testing pipeline. We will use cutting-edge and novel in vitro primary human cell co-cultures and immunocompetent mouse models to evaluate immunogenicity, chimeric and avatar mouse models to evaluate immunogenicity and efficacy and identify correlates of protection, and the highly relevant cynomolgus macaque model to evaluate safety, immunogenicity and efficacy. Furthermore, GMP batches of the best vaccine candidates will be produced by the end of the project, towards their future evaluation in a phase I clinical trial, in collaboration with the WHO-led initiative for prioritization and acceleration of clinical trials of Marburgvirus vaccines in at-risk and healthcare communities and upon outbreaks.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores